Award

Acute and chronic effects of glucocorticoids in energy homeostasis

Description: Obesity and its associated diseases are a major cause of morbidity and mortality world-wide. Endogenous glucocorticoids (GCs) play a key role in energy homeostasis and potentially contribute to the current obesity pandemic. In this project I will investigate the acute effects of GCs in response to energy intake (AIM A), the chronic effects of GCs in obesity (AIM B), and aim to counteract metabolic side effects of GCs with metformin (AIM C). AIM A) The acute effects of glucocorticoids upon food intake. Excessive food intake disrupts energy homeostasis and eventually leads to obesity. I have previously shown that in response to acute excessive food intake the body triggers a set of changes in order to maintain body weight. The underlying mechanisms of these physiological changes are poorly understood. Interestingly, GCs increase with acute food intake and many physiological adaptions to overfeeding coincide with classical GC actions.In a randomized, cross-over study I will investigate the role of GCs upon acute excessive food intake. 14 healthy volunteers will receive a block and replace therapy that mimics physiological GC rhythm (metyrapone plus hydrocortisone) or placebo. Participants will undergo two identical overfeeding periods with each treatment. With the block and replace therapy food-induced GCs will be supressed. To reveal whether GCs mediate the physiological adaptions to excessive food intake, I will compare metabolic and autonomic parameters. Understanding acute effects of GCs upon food intake is critical, since repetitive disruptions of GC secretion may become harmful in chronic conditions.AIM B) The chronic effects of glucocorticoids in obesity Environmental factors such as stress and sleep deprivation contribute to the current obesity pandemic and are known to disrupt GC secretion. Obese patients have a chronically disrupted GC physiology. Whether the dysregulation of GCs is a cause or a consequence of the obesity pandemic is unknown. In a second cross-over study, 18 obese patients will receive a block and replace therapy that restores physiological GC rhythm (metyrapone plus hydrocortisone) or placebo. After a washout-period each participant will receive the other compound. During both phases, participants will be on a balanced diet. Metabolic phenotyping will identify whether normalization of GC rhythmicity improves features of the metabolic syndrome. Understanding the role of endogenous GCs in the development of the metabolic syndrome potentially provides a new treatment target for obesity.Aim C) Counteracting deleterious metabolic glucocorticoid effects with metformin Supraphysiological doses of GCs are widely prescribed as immunosuppressants. Metabolic side effects such as obesity and diabetes are extremely common. Efforts to investigate and prevent side effects are lacking. I have previously shown that metformin prevents deterioration of glucose homeostasis during GC therapy. However, mechanisms of metformin counteracting GC-induced side effects remain poorly understood. In a randomized, controlled, cross-over study, 18 healthy volunteers will receive a five-day course of prednisone with metformin or placebo. I will use established methods to assess systemic changes in energy homeostasis and novel techniques such as metabolomics to identify underlying pathways. This will advance our understanding of energy homeostasis during GC excess, may prevent thousands of patients from GC-induced side effects and also offers a model for targeting disrupted endogenous GCs secretion (Aim B).
Amount: CHF 912,100
Funding type: fellowship
Funder scheme: Ambizione
Start date: 2021-03-01
End date: 2025-02-28
Institutions: University of Basel, University of Basel – BS
Funded outputs count: 1
Funder award ID: 193516
OpenAlex ID: G6946348289